Semaglutide 10 mg

$218.00

Size

Order total:
Semaglutide 10 mg $218.00
Guaranteed Safe Checkout

Product Name: Semaglutide

CAS No: 910463-68-2

CAT No: P100124

Molar Mass: 4113.64

Chemical Formula: C187H291N45O59

Synonyms: BGM 134, Ozempic, NN 9536

Storage: Store at -20°C

Sequence: HXEGTFTSDV SSYLEGQAAK EFIAWLVRGR G

Target: GLP-1 RA

Purity: 98%

Application:

Semaglutide (CAS: 910463-68-2) is a promising pharmaceutical compound in the realm of diabetes management. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide stimulates insulin secretion while inhibiting glucagon release, leading to improved blood glucose control. Its primary target is the GLP-1 receptor, primarily found in pancreatic islet cells. Widely recognized for its efficacy in type 2 diabetes, semaglutide has demonstrated remarkable benefits, including weight reduction and cardiovascular risk mitigation. Its mechanism of action involves enhancing glucose-dependent insulin release, suppressing appetite, and slowing gastric emptying. Beyond diabetes, ongoing research explores its potential applications in obesity treatment. Semaglutide’s multifaceted action makes it a valuable tool in the pharmaceutical arsenal for managing metabolic disorders, offering hope for improved patient outcomes in the ever-evolving landscape of diabetes care.

Current Research:

The Semaglutide Treatment Effect in People with Obesity (STEP) program, consisting of several randomized controlled clinical trials, has provided robust evidence supporting the effectiveness of semaglutide in inducing weight loss. However, questions linger regarding the applicability of these findings in real-world settings, prompting investigations into the clinical response to semaglutide outside of controlled trial environments. Real-world studies have revealed that semaglutide yields comparable weight loss outcomes to those observed in clinical trials, with patients experiencing significant reductions in body weight over a relatively short duration. Despite slight variations in baseline characteristics, such as higher baseline body mass index (BMI) and prevalence of comorbidities like hypertension and dyslipidemia, real-world patients exhibit similar responses to semaglutide treatment as seen in controlled trials.

Safety analyses of semaglutide in real-world settings have not uncovered any new safety concerns, aligning with the well-established safety profile observed in clinical trials. However, limitations in real-world studies, including patient adherence, loss to follow-up, and challenges in assessing lifestyle modifications and physical activity, underscore the need for further research to fully elucidate the long-term effects and real-world applicability of semaglutide.

In conclusion, semaglutide represents a promising pharmacological intervention for obesity management, offering tangible benefits in terms of weight loss and improvements in metabolic health. While clinical trials have provided compelling evidence of semaglutide’s efficacy and safety, real-world studies continue to validate these findings, highlighting its potential as a valuable therapeutic tool in combating the global obesity epidemic.

Target Indicators:

Semaglutide is a new generation GLP-1 (Glucagon-Like Peptide-1) analog developed by the Danish company Novo Nordisk. Semaglutide is a long-acting formulation based on the basic structure of liraglutide, and it shows better efficacy in treating type 2 diabetes. Novo Nordisk has completed six Phase IIIa studies of semaglutide injections and submitted a new drug application for once-weekly semaglutide injections to the U.S. Food and Drug Administration (FDA) on December 5, 2016. They have also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). On the other hand, once-daily oral semaglutide formulation is currently in Phase III clinical trials

Reference:

Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism, 25(1), 18-35.

Alabduljabbar, K., Alsaqaaby, M., Neff, K. J., Crotty, M., & le Roux, C. W. (2024). Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine, 83(2), 392-398.


Get a Quote

Please enable JavaScript in your browser to complete this form.
Please input the Nmae
Please input the Email
Please input the organization
Please input the Phone
Address
Please specify your needs regarding the inquired product, e.g. it's purity, apperance, application, etc.

Additional information

Amount

25mg